Royalty Pharma plc

NasdaqGS:RPRX Stock Report

Market Cap: US$22.3b

Royalty Pharma Past Earnings Performance

Past criteria checks 2/6

Royalty Pharma has been growing earnings at an average annual rate of 2.7%, while the Pharmaceuticals industry saw earnings growing at 8.5% annually. Revenues have been growing at an average rate of 1.3% per year. Royalty Pharma's return on equity is 13.5%, and it has net margins of 32.6%.

Key information

2.73%

Earnings growth rate

-1.94%

EPS growth rate

Pharmaceuticals Industry Growth5.95%
Revenue growth rate1.34%
Return on equity13.54%
Net Margin32.55%
Last Earnings Update30 Sep 2025

Recent past performance updates

Recent updates

Royalty Pharma: Investor Day Upside

Sep 12

Benign Growth For Royalty Pharma plc (NASDAQ:RPRX) Underpins Its Share Price

Jul 06
Benign Growth For Royalty Pharma plc (NASDAQ:RPRX) Underpins Its Share Price

Here's Why We Think Royalty Pharma (NASDAQ:RPRX) Is Well Worth Watching

May 31
Here's Why We Think Royalty Pharma (NASDAQ:RPRX) Is Well Worth Watching

Royalty Pharma: Delivering Growth With A Positive Story Ahead

Feb 13

Subdued Growth No Barrier To Royalty Pharma plc (NASDAQ:RPRX) With Shares Advancing 25%

Jan 29
Subdued Growth No Barrier To Royalty Pharma plc (NASDAQ:RPRX) With Shares Advancing 25%

Royalty Pharma: Key Strategic Updates To Be Priced In

Jan 15

Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.22

Jan 13
Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.22

We Think Royalty Pharma (NASDAQ:RPRX) Can Stay On Top Of Its Debt

Dec 05
We Think Royalty Pharma (NASDAQ:RPRX) Can Stay On Top Of Its Debt

Solid Earnings May Not Tell The Whole Story For Royalty Pharma (NASDAQ:RPRX)

Nov 13
Solid Earnings May Not Tell The Whole Story For Royalty Pharma (NASDAQ:RPRX)

Royalty Pharma: Massive Opportunity Ahead

Nov 09

Royalty Pharma plc Q2: Beat And Raise Reaffirm Our Buy Rating

Aug 22

Royalty Pharma: Busy Putting Capital To Work

Aug 11

Royalty Pharma: Solid Start Of The Year, Buy Confirmed

May 11

Royalty Pharma: Solid Operational Performance

Feb 19

Royalty Pharma: One Of The Best Names In Pharmaceuticals

Jan 22

Revenue & Expenses Breakdown

How Royalty Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:RPRX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 252,350765541402
30 Jun 252,3051,021479352
31 Mar 252,2641,09329052
31 Dec 242,2648592372
30 Sep 242,2661,1452282
30 Jun 242,23867322952
31 Mar 242,23979922252
31 Dec 232,3551,13525052
30 Sep 232,324184264102
30 Jun 232,36125525777
31 Mar 232,35933226177
31 Dec 222,23743227177
30 Sep 222,247507200230
30 Jun 222,259466198295
31 Mar 222,278602191298
31 Dec 212,289620183200
30 Sep 212,286783187104
30 Jun 212,23997218919
31 Mar 212,19549318721
31 Dec 202,12249518226
30 Sep 202,0081,74515534
30 Jun 201,9341,86313052
31 Mar 201,8802,05211768
31 Dec 191,8142,34910383
31 Dec 181,7951,37862393
31 Dec 171,5981,210106118

Quality Earnings: RPRX has high quality earnings.

Growing Profit Margin: RPRX's current net profit margins (32.6%) are lower than last year (50.5%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: RPRX's earnings have grown by 2.7% per year over the past 5 years.

Accelerating Growth: RPRX's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: RPRX had negative earnings growth (-33.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (9.1%).

Return on Equity

High ROE: RPRX's Return on Equity (13.5%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/10 10:57
End of Day Share Price 2025/11/07 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Royalty Pharma plc is covered by 15 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason Matthew GerberryBofA Global Research
Geoffrey MeachamCitigroup Inc
Prem ChulakiCrisp Idea